The 5th Top 50 of Innovative Biotechnology Enterprises in Guangdong-HongKong-Macao Greater Bay ceremony was held in Guangzhou, China. The list of top 50 companies was announced in the event and Pluslife was granted the Pioneer Enterprise Award. 

The Top 50 Innovative Biotechnology Enterprises in the Greater Bay Area (Top 50) were selected through sponsorship from the Zhongchuang Institute of Industry & Innovation, in conjunction with Guangdong Medical Valley, and co-organized by China CITIC Bank Guangzhou Branch. The award seeks to promote emerging companies in medical equipment supply, biomedicine development and medical service with excellent future potential, and the in-depth development of the biotech industry.

The selection criteria for the award evaluated companies based on their degree of technological innovation, future development prospects, and market application with support from technology, capital, and market dimensions. Since the first award was held in 2018, the "Top 50" has received extensive attention and reports from government authorities, scholars, experts, media, and biotech companies.

Pluslife's award in the "Top 50" demonstrates its significant advantages and potential in technological innovation, services, and market applications. With strong R&D capabilities from core proteins research to diagnosing technology development, Pluslife has applied for over 100 patents based on its self-developed RHAM technology, with over 20 of these patents authorized.

Pluslife developed the "Mini Dock," a Next-Generation Molecular POCT Analyzer based on its self-developed RHAM technology. This product offers portability, higher accuracy and sensitivity, ease of use, multi-pathogen detection, and affordability compared to typical molecular diagnostic products. It also has a multi-line hardware and software integrated solution that enables simultaneous diagnosis of multiple specimens.

Pluslife had developed molecular POCT test kits for human respiratory tract infection, reproductive tract infection, and pet disease. These products have been registered and sold worldwide in regions including the United Kingdom, Germany, and Latin America. Markets are expected to grow and capture in 2023 as a result of the products' portability, accuracy, and competitive cost natures.

The "Top 50" Pioneer Enterprise Award affirms Pluslife's past achievements and encourages its future progress. Pluslife plans to deepen the development of molecular diagnostics, upgrade existing product technology, and accelerate registration and application of new products globally. Their goal is to provide better solutions to the masses and contribute to the high-quality development of the biomedicine industry in the Greater Bay Area.